Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL

 

Arnon P. Kater, MD, PhD, Professor of Hematology, Amsterdam University Medical Center, the Netherlands, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax monotherapy in patients with relapsed/refractory CLL. These results were presented at the virtual 2020 EHA Annual Congress.

Advertisement

Advertisement

Advertisement

Advertisement